Antiverse

Antiverse uses generative AI to design antibody complementarity-determining regions (CDRs) — the parts of antibodies that bind to targets. The company's platform generates novel CDR sequences optimized for binding, developability, and manufacturability, enabling the design of antibodies against challenging targets including GPCRs and ion channels.

Generative AI platform for de novo design of antibody CDR sequences. The technology generates diverse, high-quality antibody sequences optimized for target binding and drug-like properties against challenging target classes.